{
    "nctId": "NCT04060134",
    "briefTitle": "A Retrospective Breast Reconstruction Study",
    "officialTitle": "A Retrospective, Multi-Center, Open Label Study Evaluating SimpliDerm\u2122 and Other Human Acellular Dermal Matrices in Breast Reconstruction",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 223,
    "primaryOutcomeMeasure": "Occurrence of Events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patient who underwent immediate breast reconstruction post-mastectomy; either direct to implant or with a tissue expander followed by exchange for a saline or gel implant.\n* HADMs such as: InteguPly, SimpliDerm, AlloDerm, FlexHD, DermACELL, Cortiva, or AlloMax used in the breast reconstruction.\n\nExclusion Criteria:\n\n* Female patient who underwent cosmetic/aesthetic breast augmentation procedure or revision.\n* Female patient who underwent delayed breast reconstruction procedure.\n* Female patient who underwent revision of previous breast reconstruction procedure.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}